Jafron Biomedical Co.,Ltd. (SHE:300529)

China flag China · Delayed Price · Currency is CNY
17.95
+0.22 (1.24%)
Apr 1, 2026, 3:04 PM CST
Market Cap13.73B -31.6%
Revenue (ttm)2.04B -22.6%
Net Income481.79M -40.1%
EPS0.63 -37.8%
Shares Out774.36M
PE Ratio28.17
Forward PE25.06
Dividend0.80 (4.49%)
Ex-Dividend DateMay 26, 2025
Volume3,759,900
Average Volume3,553,808
Open17.36
Previous Close17.73
Day's Range17.36 - 18.01
52-Week Range17.30 - 26.99
Beta0.43
RSI37.89
Earnings DateApr 28, 2026

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/buc... [Read more]

Sector Healthcare
Founded 1989
Employees 2,500
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300529
Full Company Profile

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.

Financial Statements